Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies

Leukemia Research

Volumn 37, Issue 11, 2013, Pages 1461-1467

  Sampath, Deepa ^a   Malik, Asifa ^a   Plunkett, William ^a   Nowak, Billie ^a   Williams, Betsy ^a   Burton, Michelle ^b   Verstovsek, Srdan ^a   Faderl, Stefan ^a   Garcia Manero, Guillermo ^a   List, Alan F ^b   Sebti, Said ^b   Kantarjian, Hagop M ^a   Ravandi, Farhad ^a   Lancet, Jeffrey E ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Akt; AML; Nucleoside analog; Phase I clinical trial; Triciribine

Indexed keywords

PROTEIN KINASE B; TRICIRIBINE PHOSPHATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; APOPTOSIS; ARTICLE; BLAST CELL CRISIS; BLEEDING; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME PHOSPHORYLATION; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; OUTCOME ASSESSMENT; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE;

AKT; AML; NUCLEOSIDE ANALOG; PHASE I CLINICAL TRIAL; TRICIRIBINE;

ACENAPHTHENES; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RIBONUCLEOTIDES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84886803658     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.07.034     Document Type: Article

References (42)

1. O'Donnell M.R., Abboud C.N., Altman J., Appelbaum F.R., Coutre S.E., Damon L.E., et al. Acute myeloid leukemia. J Natl Compr Canc Netw 2011, 9:280-317.
2. Stone R., Sekeres M., Garcia-Manero G. Evolving strategies in the treatment of MDS and AML. Clin Adv Hematol Oncol 2009, 7:1-14. quiz 2 p following.
3. Burnett A., Wetzler M., Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011, 29:487-494.
4. Jabbour E.J., Estey E., Kantarjian H.M. Adult acute myeloid leukemia. Mayo Clin Proc 2006, 81:247-260.
5. Stirewalt D.L., Meshinchi S. Receptor tyrosine kinase alterations in AML - biology and therapy. Cancer Treat Res 2011, 145:85-108.
6. Wiernik P.H. FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol 2011, 8:429-436. 44.
7. Gilliland D.G., Griffin J.D. Role of FLT3 in leukemia. Curr Opin Hematol 2002, 9:274-281.
8. Siendones E., Barbarroja N., Torres L.A., Buendia P., Velasco F., Dorado F., et al. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematol Oncol 2007, 25:30-37.
9. Testa J.R., Tsichlis P.N. AKT signaling in normal and malignant cells. Oncogene 2005, 24:7391-7393.
10. Franke T.F., Kaplan D.R., Cantley L.C., Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 1997, 275:665-668.
11. Bayascas J.R., Alessi D.R. Regulation of Akt/PKB Ser473 phosphorylation. Mol Cell 2005, 18:143-145.
12. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
13. Stephens L., Anderson K., Stokoe D., Erdjument-Bromage H., Painter G.F., Holmes A.B., et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 1998, 279:710-714.
14. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
15. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282:1318-1321.
16. Kornblau S.M., Singh N., Qiu Y., Chen W., Zhang N., Coombes K.R. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res 2011, 16:1865-1874.
17. Grandage V.L., Gale R.E., Linch D.C., Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 2005, 19:586-594.
18. Min Y.H., Eom J.I., Cheong J.W., Maeng H.O., Kim J.Y., Jeung H.K., et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 2003, 17:995-997.
19. Xu Q., Simpson S.E., Scialla T.J., Bagg A., Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003, 102:972-980.
20. Kornblau S.M., Womble M., Qiu Y.H., Jackson C.E., Chen W., Konopleva M., et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006, 108:2358-2365.
21. Min Y.H., Cheong J.W., Kim J.Y., Eom J.I., Lee S.T., Hahn J.S., et al. Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res 2004, 64:5225-5231.
22. Brandwein J.M., Hedley D.W., Chow S., Schimmer A.D., Yee K.W., Schuh A.C., et al. A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response. Leukemia 2011, 25(16):945-952.
23. Grandage V.L., Gale R.E., Linch D.C., Khwaja A. PI3-kinase//Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways. Leukemia 2005, 19:586-594.
24. Matsunaga T., Takemoto N., Sato T., Takimoto R., Tanaka I., Fujimi A., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003, 9:1158-1165.
25. Tazzari P.L., Cappellini A., Ricci F., Evangelisti C., Papa V., Grafone T., et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase//Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007, 21:427-438.
26. Powis G., Basseches P.J., Kroschel D.M., Richardson R.L., O'Connell M.J., Kvols L.K. Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials. Cancer Treat Rep 1986, 70:359-362.
27. Schweinsberg P.D., Smith R.G., Loo T.L. Identification of the metabolites of an antitumor tricyclic nucleoside (NSC-154020). Biochem Pharmacol 1981, 30:2521-2526.
28. Berndt N., Yang H., Trinczek B., Betzi S., Zhang Z., Wu B., et al. The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ 2010, 17:1795-1804.
29. Feun L.G., Blessing J.A., Barrett R.J., Hanjani P. A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A gynecologic oncology group study. Am J Clin Oncol 1993, 16:506-508.
30. Feun L.G., Savaraj N., Bodey G.P., Lu K., Yap B.S., Ajani J.A., et al. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res 1984, 44:3608-3612.
31. Hoffman K., Holmes F.A., Fraschini G., Esparza L., Frye D., Raber M.N., et al. Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer. Cancer Chemother Pharmacol 1996, 37:254-258.
32. Schilcher R.B., Haas C.D., Samson M.K., Young J.D., Baker L.H., Phase I. evaluation and clinical pharmacology of tricyclic nucleoside 5'-phosphate using a weekly intravenous regimen. Cancer Res 1986, 46:3147-3151.
33. Yang L., Dan H.C., Sun M., Liu Q., Sun X.M., Feldman R.I., et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004, 64:4394-4399.
34. Evangelisti C., Ricci F., Tazzari P., Chiarini F., Battistelli M., Falcieri E., et al. Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. J Cell Physiol 2011, 226:822-831.
35. Balasis M.E., Forinash K.D., Chen Y.A., Fulp W.J., Coppola D., Hamilton A.D., et al. Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res 2011, 17:2852-2862.
36. Gloesenkamp C.R., Nitzsche B., Ocker M., Di Fazio P., Quint K., Hoffmann B., et al. AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors. Int J Oncol 2012, 40:876-888.
37. Garrett C.R., Coppola D., Wenham R.M., Cubitt C.L., Neuger A.M., Frost T.J., et al. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs 2011, 29:1381-1389.
38. Sampath D., Cortes J., Estrov Z., Du M., Shi Z., Andreeff M., et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006, 107:2517-2524.
39. Giles F.J., Keating A., Goldstone A.H., Avivi I., Willman C.L., Kantarjian H.M. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2002, 7:3-11. 0.
40. Kantarjian H., Gandhi V., Cortes J., et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003, 102:2379-2386.
41. Kantarjian H.M., Estey E.H., Keating M.A. New chemotherapeutic agents in acute myeloid leukemia. Leukemia 1996, 10(Suppl. 1):S4-S6.
42. Keating M.J., O'Brien S., McLaughlin P., Dimopoulos M., Gandhi V., Plunkett W., et al. Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther 1996, 38(Suppl 2):S83-S91.